Physician profile
Thomas E Moran
NPI 1700876505
$891.50
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2021: $12.10 · 2022: $187.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $211.54 | 2019 | |
| Astellas Pharma US INC | $187.00 | 2022 | |
| Glaxosmithkline, LLC. | $174.88 | 2019 | |
| Allergan, INC. | $145.84 | 2019 | |
| Lilly USA, LLC | $122.78 | 2019 | |
| Pfizer INC. | $13.41 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.85 | 2019 | |
| Abbvie INC. | $12.10 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Moran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.